ClinicalTrials.gg
CompletedNCT01282424DELTAUpdated Jul 11, 2019Results posted

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

A Phase 2 interventional study of Idelalisib in Follicular Lymphoma, Small Lymphocytic Lymphoma and Lymphoplasmacytic Lymphoma, sponsored by Gilead Sciences. Completed at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-11.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.

Enrollment
3rd of 12
125 · median 18
Started
2011
with 1 other
Phase 2
5 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
7 of 12
Gilead Sciences

Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 2, and was the 1st registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing idelalisib in Lymphoma, Follicular as a file.
02

Study summary

The primary objective will be to assess the overall response rate and to evaluate the efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is refractory both to rituximab and to alkylating-agent-containing chemotherapy.

Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg taken twice per day. Treatment with idelalisib can continue in compliant participants as long as the study is still ongoing and the participants appear to be benefiting from treatment with acceptable safety.

03

Conditions studied

  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Marginal Zone Lymphoma

Keywords

  • indolent Non-Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • iNHL
  • NHL
  • GS-1101
  • CAL-101
  • PI3K
  • Phosphatidylinositol 3-kinase
  • Follicular Lymphoma (FL)
  • Small lymphocytic lymphoma (SLL)
  • Lymphoplasmacytoid lymphoma (LPL)
  • Marginal zone lymphoma (MZL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • performance status of ≥ 60 ( [ECOG] performance score of 0, 1, or 2)
  • confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:

    • Follicular lymphoma (FL)
    • Small lymphocytic lymphoma (SLL) with absolute lymphocyte count \< 5 x 10\^9/L at the time of diagnosis and on baseline laboratory assessment performed within 4 weeks prior to the start of study drug administration
    • Lymphoplasmacytic lymphoma (LPL), with or without associated Waldenstroms Macroglobulinemia (WM)
    • Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal)
  • Prior treatment with ≥ 2 prior chemotherapy-based or immunotherapy-based regimens for iNHL
  • Presence of radiographically measurable lymphadenopathy or extranodal lymphoid
  • Prior treatment with rituximab and with an alkylating agent (eg, bendamustine, cyclophosphamide, ifosfamide, chlorambucil, melphalan, busulfan, nitrosoureas) for iNHL
  • Lymphoma that is to rituximab and to an alkylating agent
  • Discontinuation of all other therapies for treatment of iNHL ≥ 3 weeks before Visit 2
  • For men and women of , willingness to abstain from sexual intercourse or employ an effective method of during the study drug administration and follow-up periods
  • Willingness and ability to provide written and to comply with the protocol requirements

Key Exclusion Criteria:

  • Central nervous system or lymphoma
  • Known histological transformation from iNHL to diffuse large B-cell lymphoma
  • History of a non-lymphoma malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer, other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for ≥ 5 years
  • Evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment
  • Pregnancy or breastfeeding
  • Ongoing alcohol or drug addiction
  • Known history of drug-induced liver injury, chronic active infection, chronic active infection, alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver, or portal hypertension
  • History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  • Ongoing therapy, including systemic . Participant may be using topical or inhaled corticosteroids.
  • Prior therapy with idelalisib
  • Exposure to another drug within 3 weeks prior to start of study treatment
  • Concurrent participation in another therapeutic treatment trial
  • Prior or ongoing illness, medical condition, surgical history, physical finding, finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant, alter the absorption, distribution, metabolism or excretion of the study drug, or impair the assessment of study results

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Idelalisib

    Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.

    Drug: Idelalisib

Interventions

  • Idelalisib 150 mg tablet administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL-101, IDELA

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a complete response (CR) or partial response (PR; or minor response \[MR\] for participants with WM) as assessed by the study independent review committee (IRC). CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. For WM only, response was defined as a reduction in immunoglobulin M (IgM) of ≥ 50% decrease for PR, and ≥ 25% decrease for MR; no increase from baseline in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions or signs and symptoms of active disease (Owen, 2013)

    Time frame: Start of Treatment to End of Treatment (up to 81 months)

Secondary outcomes

  1. Duration of Response

    Duration of Response (DOR) was defined as the interval from the first documentation of CR or PR (or MR for participants with WM) to the earlier of the first documentation of disease progression as assessed by the study IRC or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.

    Time frame: Start of Treatment to End of Treatment (up to 81 months)

  2. Lymph Node Response Rate

    Lymph node response (LNR) was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the product of the perpendicular diameters (SPD) of measurable index lesions as assessed by the study IRC.

    Time frame: Start of Treatment to End of Treatment (up to 81 months)

  3. Time to Response

    Time to response (TTR) was defined as the interval from the start of idelalisib treatment to the first documentation of CR or PR (or MR for participants with WM) as assessed by the study IRC.

    Time frame: Start of Treatment to End of Treatment (up to 81 months)

  4. Progression-Free Survival

    Progression-free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression as assessed by the study IRC or death from any cause. PFS was analyzed using KM estimates.

    Time frame: Start of Treatment to End of Treatment (up to 81 months)

  5. Overall Survival

    Overall survival (OS) was defined as the time interval from the start of idelalisib treatment to death from any cause. OS was analyzed using KM estimates.

    Time frame: Start of Treatment to Last Long-Term Follow-Up Visit (up to maximum of 7 years)

  6. Change in Health-Related Quality of Life Using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS)

    Change in health-related quality of life events were reported by participants using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS) assessment tool. Results are presented as the mean (SD) best change from baseline. The best change from baseline was defined as the highest change score (improvement) after baseline. The FACT-LymS is on a scale from 0-60, with higher scores associated with a better quality of life. It incorporates values from 15 questions, each rated 0-4, related to study indications.

    Time frame: Baseline to End of Treatment (up to 81 months)

  7. Change in Karnofsky Performance Status

    The change in Karnofsky performance status was reported as the best (highest change score) and worst (lowest change score) change from baseline using the Karnofsky performance criteria. The Karnofsky score classified participants according to their functional impairment. Scores are on a scale from 0-100, the lower the score, the worse the survival for most serious illnesses.

    Time frame: Baseline to End of Treatment (up to 81 months)

  8. Changes in Plasma Concentrations of Disease-Associated Chemokines and Cytokines

    Analysis of the cytokine/chemokine was planned to be performed on a subset of samples from this study along with a subset of samples from other studies. Therefore, data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Enrollment to End of Treatment (up to 81 months)

  9. Safety and Tolerability of Idelalisib Assessed as the Number of Participants Experiencing Adverse Events (AEs) or Abnormalities in Vital Signs, Laboratory Tests, or Electrocardiograms

    This composite endpoint measured the safety and tolerability profile of idelalisib. "Clinically meaningful" abnormalities in vital signs and electrocardiograms (ECG) were as determined by the investigator.

    Time frame: Start of Treatment to End of Treatment (up to 81 months) plus 30 days

  10. Study Drug Exposure

    The average idelalisib exposure was summarized.

    Time frame: Start of Treatment to End of Treatment (up to 81 months)

  11. Idelalisib Plasma Concentration

    Time frame: Predose and at 1.5 hours (± 5 minutes) postdose on Day 29

  12. PK Parameter: Cmax

    Cmax at Days 1 and 29 was analyzed. Cmax is defined as the maximum concentration of drug.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29

  13. PK Parameter: Tmax

    Tmax at Days 1 and 29 was analyzed. Tmax is defined as the time of Cmax (the maximum concentration of drug).

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29

  14. PK Parameter: AUClast

    AUClast at Days 1 and 29 was analyzed. AUClast is defined as the concentration of drug from time zero to the last observable concentration

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29

07

Results

Posted Sep 4, 2014

Participant flow

Participants were enrolled at a total of 54 study sites in North America and Europe. The first participant was screened on 04 March 2011. The last participant observation was on 16 May 2018.

Treatment Period (TP) (81 Months)
Participant flow — Treatment Period (TP) (81 Months)
MilestoneIdelalisib
Started125
Completed: disease progression70
Completed: death9
Completed79
Not completed46
Withdrew: Adverse event30
Withdrew: Withdrew consent6
Withdrew: Investigator request7
Withdrew: Other (unknown)3
Long-term Follow-up Period (5 Years)
Participant flow — Long-term Follow-up Period (5 Years)
MilestoneIdelalisib
Started84
Completed20
Not completed64
Withdrew: Withdrew consent2
Withdrew: Death40
Withdrew: Lost to follow-up1
Withdrew: Other (unknown)21

Outcome measures

PrimaryOverall Response Rate

Overall response rate (ORR) was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a complete response (CR) or partial response (PR; or minor response \[MR\] for participants with WM) as assessed by the study independent review committee (IRC). CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined as a ≥ 50% reduction in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions. For WM only, response was defined as a reduction in immunoglobulin M (IgM) of ≥ 50% decrease for PR, and ≥ 25% decrease for MR; no increase from baseline in the sum of the products of the longest perpendicular diameters of all index lesions, with no new lesions or signs and symptoms of active disease (Owen, 2013)

Time frame:
Start of Treatment to End of Treatment (up to 81 months)
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsIdelalisib
Overall Response Rate57.6 (48.4 to 66.4)
Statistical analysis
  • Idelalisib · Exact binomial test · p = < 0.0001 (The null hypothesis is ≤ 20%.)
SecondaryDuration of Response

Duration of Response (DOR) was defined as the interval from the first documentation of CR or PR (or MR for participants with WM) to the earlier of the first documentation of disease progression as assessed by the study IRC or death from any cause. DOR was analyzed using Kaplan-Meier (KM) estimates.

Time frame:
Start of Treatment to End of Treatment (up to 81 months)
Reported as:
Median · months
Duration of Response
monthsIdelalisib
Duration of Response12.5 (6.2 to 28.6)
SecondaryLymph Node Response Rate

Lymph node response (LNR) was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the product of the perpendicular diameters (SPD) of measurable index lesions as assessed by the study IRC.

Time frame:
Start of Treatment to End of Treatment (up to 81 months)
Reported as:
Number · percentage of participants
Lymph Node Response Rate
percentage of participantsIdelalisib
Lymph Node Response Rate56.8 (47.6 to 65.6)
SecondaryTime to Response

Time to response (TTR) was defined as the interval from the start of idelalisib treatment to the first documentation of CR or PR (or MR for participants with WM) as assessed by the study IRC.

Time frame:
Start of Treatment to End of Treatment (up to 81 months)
Reported as:
Median · months
Time to Response
monthsIdelalisib
Time to Response2.0 (1.8 to 4.2)
SecondaryProgression-Free Survival

Progression-free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression as assessed by the study IRC or death from any cause. PFS was analyzed using KM estimates.

Time frame:
Start of Treatment to End of Treatment (up to 81 months)
Reported as:
Median · months
Progression-Free Survival
monthsIdelalisib
Progression-Free Survival11.1 (8.3 to 14.0)
SecondaryOverall Survival

Overall survival (OS) was defined as the time interval from the start of idelalisib treatment to death from any cause. OS was analyzed using KM estimates.

Time frame:
Start of Treatment to Last Long-Term Follow-Up Visit (up to maximum of 7 years)
Reported as:
Median · months
Overall Survival
monthsIdelalisib
Overall Survival48.6 (33.9 to 71.7)
SecondaryChange in Health-Related Quality of Life Using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS)

Change in health-related quality of life events were reported by participants using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS) assessment tool. Results are presented as the mean (SD) best change from baseline. The best change from baseline was defined as the highest change score (improvement) after baseline. The FACT-LymS is on a scale from 0-60, with higher scores associated with a better quality of life. It incorporates values from 15 questions, each rated 0-4, related to study indications.

Time frame:
Baseline to End of Treatment (up to 81 months)
Reported as:
Mean · units on a scale
Change in Health-Related Quality of Life Using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS)
units on a scaleIdelalisib
Change in Health-Related Quality of Life Using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS)10.3 ± 17.08
SecondaryChange in Karnofsky Performance Status

The change in Karnofsky performance status was reported as the best (highest change score) and worst (lowest change score) change from baseline using the Karnofsky performance criteria. The Karnofsky score classified participants according to their functional impairment. Scores are on a scale from 0-100, the lower the score, the worse the survival for most serious illnesses.

Time frame:
Baseline to End of Treatment (up to 81 months)
Reported as:
Mean · units on a scale
Change in Karnofsky Performance Status
units on a scaleIdelalisib
Best change3.0 ± 8.71
Worst change-10.7 ± 12.61
SecondaryChanges in Plasma Concentrations of Disease-Associated Chemokines and Cytokines

Analysis of the cytokine/chemokine was planned to be performed on a subset of samples from this study along with a subset of samples from other studies. Therefore, data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Enrollment to End of Treatment (up to 81 months)

Results for this outcome have not been posted.

SecondarySafety and Tolerability of Idelalisib Assessed as the Number of Participants Experiencing Adverse Events (AEs) or Abnormalities in Vital Signs, Laboratory Tests, or Electrocardiograms

This composite endpoint measured the safety and tolerability profile of idelalisib. "Clinically meaningful" abnormalities in vital signs and electrocardiograms (ECG) were as determined by the investigator.

Time frame:
Start of Treatment to End of Treatment (up to 81 months) plus 30 days
Reported as:
Count of participants · Participants
Safety and Tolerability of Idelalisib Assessed as the Number of Participants Experiencing Adverse Events (AEs) or Abnormalities in Vital Signs, Laboratory Tests, or Electrocardiograms
ParticipantsIdelalisib
Any AE123
AE leading to drug discontinuation35
Serious AE72
Vital signs abnormal - clinically meaningful0
ECG abnormal - clinically meaningful0
Grade 3 or 4 hemoglobin2
Grade 3 or 4 neutrophils35
Grade 3 or 4 platelets9
Grade 3 or 4 alanine aminotransferase16
Grade 3 or 4 aspartate aminotransferase11
SecondaryStudy Drug Exposure

The average idelalisib exposure was summarized.

Time frame:
Start of Treatment to End of Treatment (up to 81 months)
Reported as:
Mean · months
Study Drug Exposure
monthsIdelalisib
Study Drug Exposure13.2 ± 15.08
SecondaryIdelalisib Plasma Concentration
Time frame:
Predose and at 1.5 hours (± 5 minutes) postdose on Day 29
Reported as:
Mean · ng/mL
Idelalisib Plasma Concentration
ng/mLIdelalisib
Predose471.6 ± 486.53
Postdose2187.7 ± 1050.76
SecondaryPK Parameter: Cmax

Cmax at Days 1 and 29 was analyzed. Cmax is defined as the maximum concentration of drug.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29
Reported as:
Mean · ng/mL
PK Parameter: Cmax
ng/mLIdelalisib
Cmax at Day 12647.5 ± 1084.99
Cmax at Day 292258.8 ± 809.61
SecondaryPK Parameter: Tmax

Tmax at Days 1 and 29 was analyzed. Tmax is defined as the time of Cmax (the maximum concentration of drug).

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29
Reported as:
Mean · hours
PK Parameter: Tmax
hoursIdelalisib
Tmax at Day 11.00 (0.99 to 1.04)
Tmax at Day 291.00 (0.95 to 2.00)
SecondaryPK Parameter: AUClast

AUClast at Days 1 and 29 was analyzed. AUClast is defined as the concentration of drug from time zero to the last observable concentration

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Days 1 and 29
Reported as:
Mean · hours x ng/mL
PK Parameter: AUClast
hours x ng/mLIdelalisib
AUClast at Day 19094.76 ± 2960.391
AUClast at Day 299293.39 ± 3996.826

Adverse events

Collected over Adverse Events: Start of Treatment to End of Treatment (up to 81 months) plus 30 days; All-Cause Mortality: Baseline to Last Long-Term Follow-Up Visit (up to maximum of 7 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib64/125 (51.2%)72/125 (57.6%)123/125 (98.4%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventIdelalisib
PyrexiaGeneral disorders15/125
PneumoniaInfections and infestations15/125
DiarrhoeaGastrointestinal disorders11/125
Febrile neutropeniaBlood and lymphatic system disorders5/125
ColitisGastrointestinal disorders5/125
DehydrationMetabolism and nutrition disorders4/125
Acute kidney injuryRenal and urinary disorders4/125
NeutropeniaBlood and lymphatic system disorders3/125
Peripheral swellingGeneral disorders3/125
DyspnoeaRespiratory, thoracic and mediastinal disorders3/125
Most frequent other events
Showing 10 of 50
Most frequent other events
EventIdelalisib
DiarrhoeaGastrointestinal disorders59/125
FatigueGeneral disorders40/125
CoughRespiratory, thoracic and mediastinal disorders40/125
NauseaGastrointestinal disorders38/125
NeutropeniaBlood and lymphatic system disorders35/125
PyrexiaGeneral disorders34/125
ThrombocytopeniaBlood and lymphatic system disorders23/125
Upper respiratory tract infectionInfections and infestations23/125
Decreased appetiteMetabolism and nutrition disorders23/125
DyspnoeaRespiratory, thoracic and mediastinal disorders22/125

Baseline characteristics

ITT analysis set included enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Idelalisib
Mean62 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib
Female45
Male80
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib
Race — White/Caucasian110
Race — Black or African American2
Race — Asian3
Race — American Indian or Alaska Native1
Race — Other8
Race — Missing1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib
Ethnicity — Hispanic or Latino6
Ethnicity — Not Hispanic or Latino117
Ethnicity — Missing2
Region of Enrollment
Region of Enrollment(Participants)Idelalisib
France10
United States83
Poland8
Germany10
United Kingdom8
Italy6
Karnofsky Performance Status
Karnofsky Performance Status(Participants)Idelalisib
Score = 602
Score = 706
Score = 8027
Score = 9044
Score = 10046
Baseline Disease History
Baseline Disease History(Participants)Idelalisib
Folicular lymphoma72
Small lymphocytic lymphoma28
LPL/WM10
Marginal zone lymphoma15
08

Study locations

41 sites
  • St. Jude Medical Center
    Fullerton, California 92835, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813-3244, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Central Coast Medical Oncology
    Santa Maria, California 93454, United States
  • Stanford Cancer Center
    Stanford, California 94035-5796, United States
  • Collaborative Research Group, LLC
    Boynton Beach, Florida 33435, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322-1013, United States
  • Northwestern University Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • John Theurer Cancer Center Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • University of Medicine and Dentistry of NJ
    New Brunswick, New Jersey 08901-1914, United States
  • Weill Cornell -New York Presbyterian Hospital
    New York, New York 10002, United States
  • Montefiore Medical Center
    New York, New York 10467, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • South Carolina Oncology Associates
    Columbia, South Carolina 29210, United States
  • Chattanooga Hem/Oncology Ass (SCRI)
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • University of Virginia Medical Center
    Charlottesville, Virginia 22908, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • University of Wisconsin
    Madison, Wisconsin 53792-5156, United States
  • CHU Morvan
    Brest, 29609, France
  • Centre Hospitalier de Lyon Sud
    Pierre Benite, 69310, France
  • Centre Henri Bequerel
    Rouen, 76038, France
  • CHU Bretonneau - Centre Kaplan
    Tours, 37044, France
  • Charité Campus Virchow Klinikum
    Berlin, 13353, Germany
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Klinikum der Universität München-Großhadern
    München, 81377, Germany
  • Universitatsklinikum Ulm
    Ulm, 89081, Germany
  • Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi
    Bologna, 40138, Italy
  • A.O.U. San Martino
    Genova, 16132, Italy
  • Fondazione Centro San Raffaele del Monte Tabor
    Milano, 20132, Italy
  • Università "Sapienza"
    Rome, 00161, Italy
  • Małopolskie Centrum Medyczne
    Kraków, 30-510, Poland
  • Centrum Onkologii w Warszawie
    Warsaw, 02-781, Poland
  • St James's Institute of Oncology
    Leeds, LS9 7TF, United Kingdom
  • St Bartholemews Hospital
    London, EC1M 6BQ, United Kingdom
  • Sarah Cannon Institute
    London, W1G 6AD, United Kingdom
  • The Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Publications

  • Salles GA, Kahl, BS, Wagner-Johnston ND, et al. Interim results from a phase 2 study of PI3Kδ inhibitor idelalisib in patients with relapsed indolent non-Hodgki lymphoma (iNHL) refractory to both rituximab and an alkylating agent. 12th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, June 19-22, 2013 Abstract No: 064bis.
  • Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22. PubMed 24450858 ↗
  • Ma S, Chan RJ, Gu L, Xing G, Rajakumaraswamy N, Ruzicka BB, Wagner-Johnston ND. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e432-e448. doi: 10.1016/j.clml.2020.12.016. Epub 2020 Dec 24. PubMed 33516721 ↗
  • Barrientos JC, Hillmen P, Salles G, Sharman J, Stilgenbauer S, Gurtovaya O, Xing G, Ruzicka B, Bhargava P, Ghia P, Pagel JM. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leuk Lymphoma. 2021 Apr;62(4):837-845. doi: 10.1080/10428194.2020.1845339. Epub 2020 Dec 10. PubMed 33297794 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in May 2018, 85 months.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 85 months is above that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2011
First posted
Jan 25, 2011
StartActual
Mar 18, 2011
Primary completionActual
May 2, 2018
CompletionActual
May 16, 2018
Results delay requested
Mar 20, 2014
Results first posted
Sep 4, 2014
Last update
Jul 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01282424
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 25, 2011
Start date
Mar 18, 2011
Primary completion
May 2, 2018
Completion
May 16, 2018
Results posted
Sep 4, 2014
Last update
Jul 11, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion